RVMD Q4 2025 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$5M

Operating Income

-$362M

Net Income

-$365M

EPS (Diluted)

$-1.90

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$274M

Free Cash Flow

-$276M

Stock-Based Comp.

$34M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$723M

Stockholders' Equity

$1.6B

Cash & Equivalents

$384M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$5M	$0	—
Operating Income	-$362M	-$216M	-67.2%
Net Income	-$365M	-$195M	-87.5%